LPS antibodies was of the IgG class. Clinical evaluation of E. coli 0157-toxoid conjugates is planned.
Escherichia coli 0157:H7, an emerging infectious agent, was first recognized as a human pathogen in 1983 (6, 25, 29, 47, 60) . Diseases caused by this pathogen have subsequently been recognized worldwide (1-5, 7-10, 12, 19-21, 25, 26, 28-30, 32, 37, 39-42, 45-47, 50-55, 60) . Infection with E. coli 0157 causes a spectrum of illnesses with high morbidity and mortality, ranging from watery diarrhea to hemorrhagic colitis and the extraintestinal complication of hemolytic-uremic syndrome (HUS) (3-10, 20, 21, 26, 28, 29, 32, 39, 40, 52, 55) . HUS can lead to acute renal failure requiring dialysis, and in children and infants this complication has a considerable mortality. In some studies, E. coli 0157 was the most common cause of dysentery in patients seen in hospital clinics (6, 29, 32, 41) .
E. coli associated with HUS produces one or two toxins similar to the Shiga toxin: the exotoxin of Shigella dysenteriae serotype 1 (Shiga-like toxin 1 [SLT-I]) or a toxin structurally and functionally related but not identical to Shiga toxin (SLT-II) (1, 7, 12, 26, 28, 34-36, 40, 42, 51-54) . Infection with SLT-containing organisms has been correlated with HUS, and E. coli 0157:H7 is a common serotype that produces these toxins. However, strains of E. coli 0157 without an SLT have been isolated from patients with hemorrhagic colitis (1) . There are no licensed vaccines for enteric infections caused by E. coli or related bacteria such as shigellae.
There is increasing evidence that serum antibodies to the surface polysaccharides, such as the Vi capsular polysaccharide of Salmonella typhi and the lipopolysaccharide (LPS) of Salmonella typhimunium, Vibrio cholerae, and shigellae, may confer protective immunity to these enteric pathogens (14, 22, 31, 48, 49, 56) . The objective of this study was to prepare conjugates with the 0-specific polysaccharide of E. coli 0157:H7 in a clinically acceptable form.
The 0-specific polysaccharide of E. (11, 49) . Polysaccharide (5 mg/ml of saline) was brought to pH 10.5 to 11.0 with 0.1 M NaOH, and an equal amount of cyanogen bromide (1 g/ml of acetonitrile) was added. The reaction was carried out for 6 min on ice, and the pH was maintained at 10.5 to 11.0 with 0.1 M NaOH. An equal volume of 0.8 M ADH in 0.5 M NaHCO3 was added, and the pH was adjusted to 8.5 with 0.1 M HCl. The reaction mixture was stirred at 3 to 8°C overnight and then dialyzed against saline at the same temperature for 24 h. The outer fluid was changed to water, and dialysis was continued for 2 days with four changes of water. The contents of the dialysis bag were freeze-dried, reconstituted in water (-10 mg/ml), and passed through a P-10 or a G-50 Sephadex column in water, and the void volume fractions were pooled and freeze-dried. The ADH-derivatized materials were designated O-SP-AH or DeA-LPS-AH.
Conjugation of polysaccharide-AH with proteins. Polysaccharides-AH were dissolved in saline at 5 mg/ml. An equal weight of protein was added, and the pH was adjusted to 5.1 to 5.5 with 0.1 M HCl. EDAC was added to a final concentration of 0.05 M, and the pH was maintained at 5.1 to 5.5 on ice for 4 h. The reaction mixture was dialyzed at 3 to 8°C against saline for 2 days with four changes of the outer fluid and then passed through a column (1.5 by 90 cm) of CL-6B Sepharose in saline.
Analyses. The molecular sizes of LPS, O-SP, and DeA-LPS were estimated by gel filtration through Superose 12 in 0.2 M NaCl-0.001 M EDTA-0.01 M Tris-0.25% deoxycholic acid (pH 8.0) by using dextrans as standards. The extent of derivatization of O-SP and DeA-LPS with ADH was measured by using TNBS with ADH as a standard, protein was measured by using the bicinchoninic acid reagent with BSA as a standard, and hexose was measured by the anthrone reaction with O-SP as a standard (11) . LPS was detected by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis with silver staining (58) . '3C nuclear magnetic resonance spectroscopy of O-SP and DeA-LPS (20 mg/ml in D20) was recorded on a GN300 spectrometer at room temperature and averaged more than 42,000 scans.
Bioassays. protein, or conjugates (based on 2.5 ,ug per saccharide). Mice from each experimental group of 10 were exsanguinated 7 days after each injection (11, 49) . One group of mice injected three times with DeA-LPS-CW was bled again 4 months after the third injection.
Serology. Double immunodiffusion was performed in 1% agarose in phosphate-buffered saline (PBS). LPS and protein antibody levels were determined by an enzyme-linked immunosorbent assay (ELISA) using Immulon 4 plates (Dynatech, Chantilly, Va.) (11, 56, 57) . Each well of the plate was coated with 100 RI of either LPS (10 ,ug/ml) or protein (20 ,ug/ml) in PBS. LPS and protein antibody levels were expressed in ELISA units by using the hyperimmune serum; assigned a value of 100 ELISA units, as a reference.
Statistical analysis. Antibody levels are expressed as a geometric mean. Antibody concentrations below the sensitivity of the ELISA were assigned the value of one-half of that level. Comparison of geometric means was performed with either the two-sided t test or the Wilcoxon test.
RESULTS
Characterization of LPS, DeA-LPS, and O-SP. The 13C nuclear magnetic resonance spectra for O-SP and DeA-LPS were identical and in agreement with published data (Fig. 1 The LPS, DeA-LPS, and O-SP had <1% protein or nucleic acids.
Characterization of conjugates ( Table 1 ). The degree of derivatization with adipic acid hydrazide (AH) was -3% (weight/weight) for 0-SP and -2% (weight/weight) for DeA-LPS. The O-SP-AH derivative formed a line of identity with O-SP when reacting with the hyperimmune 0157 serum in double immunodiffusion (Fig. 3) . Similar results were observed with DeA-LPS and its ADH derivative (not shown).
The gel filtration profile of 0-SP-BSA through a CL-6B Sepharose column is shown in Fig. 4 . Antisera to BSA and 0157 formed a line of identity when reacted against fractions 5) . The gel filtration proffle of the conjugates with CW were similar and showed the major peak to be in the void volume and a smaller shoulder; all fractions in this peak yielded a line of identity with 0157 and CW antisera (not shown). The 0-SP-rEPA emerged as a single peak in the void volume of the CL-6B Sepharose column, and all fractions gave an identical line of precipitation with the 0157 hyperimmune and goat anti-P. aeruginosa exotoxin A sera (not shown). DeA-LPSrEPA showed a major peak in the void volume (fractions 15 to 22 [DeA-LPS-rEPA1]) and a shoulder (fractions 23 to 36 [DeA-LPS-rEPA2]). DeA-LPS-rEPA1 gave an identity line with the two antisera, and DeA-LPS-rEPA2 showed a slight spur for the 0157 hyperimmune serum over the anti-P. aeruginosa exotoxin A serum (not shown). The yield of saccharide in the conjugates was -10% for DeA-LPS-BSA and 0-SP-rEPA and 40 to 50% for the others.
LPS antibodies. Total LPS antibodies were measured in mice injected with the BSA and CW conjugates ( Table 2) Immunoglobulin G (IgG) and IgM LPS antibodies (Table  3) . O-SP, DeA-LPS, and saline did not elicit detectable LPS antibodies after three injections (data not shown). The DeA-LPS-rEPA conjugates elicited IgG antibodies only after the second injection (P < 0.01) and a booster response after the third injection (P = 0.02). The levels elicited by O-SP-rEPA (6.26 ELISA units) were higher than those of DeA-LPS-rEPA1 (4.49 ELISA units) and DeA-LPS-rEPA2 (5.10 ELISA units) but these differences were not significant.
Slight rises of IgM antibodies followed the first two injections of the three conjugates. DeA-LPS-rEPA1 elicited a slight rise after the third injection (0.94 versus 0.11 ELISA units [P = 0.004]).
Bactericidal antibodies (Table 4) . No bactericidal activity b *, P < 0.01 when compared with the value for 0-SP-rEPA after the first injection; *P, P> 0.02 when compared with the value for the same immunogen after the second injection; ** *, P < 0.07 when compared with the value for the same immunogen after the second injection.
was detected in mice injected with saline, 0-SP, or DeA-LPS (data not shown). High-titered sera were taken from the mice injected with the conjugates. In the first experiment, both the hyperimmune and conjugate-induced sera showed bactericidal activities against E. coli 0157:H7. Similarly, conjugates prepared with rEPA as the carrier and 0-SP and DeA-LPS also elicited 0157 LPS antibodies with bactericidal activity (Table  4 , experiment 2). Absorption with LPS or DeA-LPS removed the bactericidal activity of the sera from mice injected with the conjugates as well as heat-killed E. coli 0157. Antibodies to CW (Table 5) . 0-SP and DeA-LPS alone did not elicit CW antibodies after three injections. Both conjugates elicited low levels of antibodies following the second injection and booster responses after the third injection. Each conjugate contained 2.5 ,ig of polysaccharide and 1.5 ,ug of protein per injection, and both elicited the same levels of antibodies after the third injection. Injection of 2.5 ,ug of CW alone elicited higher antibody levels after the third injection than the conjugates, but this difference was not significant (1.66 versus 0.91 ELISA units [not significant]). The conjugate-induced CW antibody levels fell slightly 4 months after the third injection (not significant).
require small inocula since the U.S. Department of Agriculture (courtesy of Ann-Marie McNamara) determined that -4 E. coli 0157 organisms per g of frozen hamburger patties were present in one outbreak, and both cause similar intestinal and extraintestinal symptoms (15, 44, 48) . We suggested that the pathogeneses of and protective immunities to shigellae and nontyphoidal salmonellae were similar (48) . We showed that 0-SP conjugates induce protective immunity mediated by serum LPS antibodies against S. typhimurium in mice (59) . It has been difficult to develop vaccines for shigellae because these pathogens are inhabitants of and pathogens for humans only. Convalescence from shigellosis confers LPS-specific protective immunity, even in children, although this immunity is incomplete and of limited duration (18, 48, 49) . Cohen et al. showed that resistance to shigellosis correlated with levels of preexisting serum IgG LPS antibodies in Israel Defense Forces recruits (14) . Preliminary data showed that immunization with a Shigella sonnei O-SP conjugate conferred protection against shigellosis in Israel Defense Forces recruits (13) . Our development of 0-specific polysaccharide-protein conjugates for prevention of enteritis caused by E. coli 0157 is based upon these data.
Strains of E. coli 0157 have been isolated worldwide from
DISCUSSION
The synthetic scheme used for conjugates of H. influenzae type b and S. dysenteriae type 1 were applied to the 0157 LPS of E. coli (11, 22, 49, 57) . Our 0157 conjugates had low levels of endotoxin and elicited serum LPS antibodies with bactericidal activity. Small amounts of free O-SP (0-SP-BSA2) or DeA-LPS (DeA-LPS-rEPA2) did not seem to alter the serum antibody responses. As observed with our 0-specific polysaccharide conjugates of shigellae, IgG was the main component of these vaccine-induced serum LPS-specific antibodies (11, 22, 49, 56, 57 There are no data about disease-acquired protective immunity to E. coli 0157 infection. High levels of LPS antibodies in patients follow infection with E. coli 0157 (3, 9) . Serumneutralizing antibodies to the SLTs, in contrast, are reported to occur infrequently and in low titers (7) . Although listed separately, E. coli and shigellae should be considered members of the same species on the basis of: (i) -80% homology between their DNAs in hybridization studies, (ii) multilocus enzyme electrophoretic typing, (iii) similarities between their 0-specific polysaccharides, and (iv) similarities between SLTs produced by both E. coli 0157 and S. dysenteriae type 1 (Shiga's bacillus) (12, 16, 34, 35, 48) . Both of these pathogens We have been interested in evaluating medically useful bacterial toxoids other than tetanus and diphtheria toxoids as carrier proteins (49) . CW was used as a carrier protein because this toxoid has been used successfully to prevent a serious enteric infection, known as Pig Bel (pig belly or gastroenteritis necroticans), in infants and children in New Guinea and other parts of the world (27) . Pig Bel toxoid (CW) was an effective carrier protein for E. coli 0157 0-SP and permitted a high yield of conjugate similar to that obtained with BSA. Because of our experience with rEPA as a carrier, we plan to use this protein first as a carrier for the 0157 conjugate vaccine (17, 57) .
